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Abstract
Aims Normoglucose tolerant (NGT) subjects with a 1-h
postload plasma glucose (PLPG) value C155 mg/dL have
an increased risk of type-2 diabetes and subclinical organ
damage. Heart rate variability (HRV) reflects cardiac au-
tonomic balance, frequently impaired in course of diabetes.
At this time, no data support the association between 1-h
PLPG and HRV; thus, we investigated the possible asso-
ciation between 1-h PLPG and HRV.
Methods We enrolled 92 never-treated hypertensive
subjects (56 women, 36 men), aged 55 ± 9.8 years. During
OGTT, the patients underwent electrocardiographic
recordings to evaluate HRV in the time domain (SDNN).
Insulin sensitivity was assessed by Matsuda index.
Results Among participants, 56 were NGT, 20 had im-
paired glucose tolerance (IGT), and 16 had type-2 diabetes.
According to the 1-h PLPG cutoff point of 155 mg/dL, we
divided NGT subjects into: NGT \ 155 (n = 38) and
NGT C 155 (n = 18). Glucose tolerance status was asso-
ciated with a significant (P \ 0.0001) increase in PLPG
and insulin and the reduction in Matsuda index. In all
groups, the SDNN values significantly (P \ 0.0001) de-
creased during the first hour of OGTT. A complete re-
covery in NGT groups was observed at the end of the
second hour; in IGT and type-2 diabetes, SDNN remained
significantly lower with respect to baseline values. At
multiple regression analysis, Matsuda index resulted in the
only determinant of SDNN modification, explaining the
12.3 % of its variability.
Conclusions Our data demonstrate that during OGTT,
sympathovagal balance is acutely affected by both glucose
and insulin modifications. Particularly, NGT C 155 sub-
jects behave in the same way of IGT and type-2 diabetes
patients.
Keywords Insulin resistance  Heart rate variability 
Glucose tolerance  Essential hypertension
Introduction
Cardiovascular diseases, particularly coronary heart dis-
ease and ischemic stroke, are the most important cause of
morbidity and mortality in subjects with type-2 diabetes
[1, 2]. In addition, type-2 diabetes-related metabolic dis-
orders lead to the appearance and progression of sensitive
and autonomic neuropathy in addition to micro- and
macro-vascular damage. Specifically, diabetic autonomic
neuropathy (DAN) is a serious and common complication
of type-2 diabetes that, despite its significant negative
impact on survival and quality of life, remains a poorly
recognized and understood clinical condition [3–5].
Damage of the autonomic nerve fibers that innervate the
Managed by Antonio Secchi.
& Francesco Perticone
perticone@unicz.it
1 Department of Experimental and Clinical Medicine,
University Magna Graecia of Catanzaro, Campus
Universitario di Germaneto, V.le Europa, 88100 Catanzaro,
Italy
2 Department of Medical and Surgical Sciences, University
Magna Græcia of Catanzaro, Campus Universitario di
Germaneto, V.le Europa, 88100 Catanzaro, Italy
3 Department of Health Science, University Magna Græcia of
Catanzaro, Catanzaro, Italy
4 Biomedical Department of Internal Medicine and Speciality,
University of Palermo, Palermo, Italy
123
Acta Diabetol
DOI 10.1007/s00592-015-0740-1
heart and blood vessels generates DAN, resulting in ab-
normalities in vascular function and heart rate variability
(HRV), the earliest indicator of DAN [6, 7].
Chronic, as so as postload/postprandial hyperglycemia,
increases the risk of cardiovascular events, irrespective of
glycemic control [8–13]. Increased oxidative stress has
been suggested as a pathophysiologic mechanism to ex-
plain this relationship [14]. In addition, there are evi-
dences demonstrating that glucose metabolism worsening,
tested by an oral glucose tolerance test (OGTT), is more
strongly associated with both subclinical target organ
damage and atherosclerotic disease; particularly, subjects
with impaired glucose tolerance (IGT) and/or impaired
fasting glucose (IFG) are characterized by an unfavorable
cardiovascular risk profile [15]. These findings have a
clinical relevance because they demonstrate that
metabolic alterations induce degenerative complications
in both prediabetic status and clinical overt disease. In
particular, in a recent paper, insulin resistance was
strongly associated with the coronary mortality in non-
diabetic men [16]. In addition, a good glyco-metabolic
control is able to delay microvascular complication ap-
pearance [17, 18].
Recent evidences demonstrated that a cutoff point of
155 mg/dL for the 1-h postload plasma glucose (PLPG)
during an OGTT identifies subjects with normal glucose
tolerance (NGT) at high risk of type-2 diabetes [19]. In
addition, we demonstrated that a 1-h PLPG value is
strongly associated with different subclinical organ damage
[20–23], all independent predictors of subsequent cardio-
vascular events [12, 24, 25]. For these evidences, we
suggested the utility to re-evaluate the concept that NGT
subjects are a homogeneous group at low risk, emphasizing
the importance of the phenotypic characterization in
defining the global cardiovascular and metabolic risk [26].
At this moment, no data are available on autonomic
modifications during an acute oral glucose load, providing
important information on autonomic response. Taken to-
gether, we designed this study to address the question
whether both glucose tolerance status and 1-h PLPG
levels, during an OGTT, may affect autonomic (dys)-
function in a group of never-treated hypertensive Cau-
casian subjects.
Research design and methods
Study population
The study group consisted of 92 uncomplicated hyperten-
sive outpatients, 56 men and 36 women aged 32–71 years
(mean ? SD = 55.0 ? 9.8), participating to the Catanzaro
Metabolic Risk factors Study (CATAMERIS) [23–26]. All
patients were Caucasian and underwent physical ex-
amination and review of their medical history. Causes of
secondary hypertension were excluded by appropriate
clinical and biochemical tests. Other exclusion criteria
were history or clinical evidence of coronary, valvular
heart disease, congestive heart failure, cardiac arrhythmia,
hyperlipidemia, peripheral vascular disease, chronic gas-
trointestinal diseases associated with malabsorption,
chronic pancreatitis, history of any malignant disease,
history of alcohol or drug abuse, liver or kidney failure and
treatments able to modify glucose metabolism. No patient
had ever been treated with antihypertensive drugs. All
subjects underwent anthropometrical evaluation measuring
weight, height and body mass index (BMI).
After 12-h fasting, a 75 g OGTT was performed with 0-,
30-, 60-, 90- and 120-min sampling for plasma glucose and
insulin. Glucose tolerance status was defined on the basis
of OGTT using the World Health Organization (WHO)
criteria. Insulin sensitivity was evaluated using the Mat-
suda index [insulin sensitivity index (ISI)], calculated as
follows: 10,000/square root of [fasting glucose (mmol/
L) 9 fasting insulin (mU/L)] 9 [mean glucose 9 mean
insulin during OGTT]. The Matsuda index is strongly re-
lated to euglycemic hyperinsulinemic clamp that represents
the gold standard test for measuring insulin sensitivity [27].
The ethical committee approved the protocol, and informed
written consent was obtained from all participants. All the
investigations were performed in accordance with the
principles of the Declaration of Helsinki.
Blood pressure measurements
Readings of clinic blood pressure (BP) were obtained in the
left arm of the supine patients, after 5 min of quiet rest,
with a mercury sphygmomanometer. Baseline BP values
were the average of the last two of the three consecutive
measurements obtained at intervals of 3 min. Patients with
a clinic systolic BP [ 140 mmHg (SBP) and/or diastolic
BP [ 90 mmHg (DBP) were defined as hypertensive.
Laboratory determinations
All laboratory measurements were performed after at least
12 fasting hours. Plasma glucose was determined immedi-
ately by the glucose oxidase method. Triglyceride, total,
low- and high-density lipoprotein (LDL, HDL) cholesterol
concentrations were measured by enzymatic methods
(Roche Diagnostics GmbH, Mannheim, Germany). Serum
insulin was determined in duplicate by a highly specific
radioimmunoassay using two monoclonal antibodies: intra-
assay CV 2.1 %, inter-assay CV 2.9 %. Hs-CRP was
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measured with a high-sensitivity immunoturbidimetric
assay on the Hitachi 917 autoanalyzer (Roche Diagnostics,
Indianapolis, Ind). Values of estimated glomerular filtra-
tion rate (e-GFR) (mL/min/1.73 m2) were calculated by
using the equation proposed by investigators in the chronic
kidney disease epidemiology (CKD-EPI) collaboration.
We preferred this equation because it is more accurate in
subjects with GFR [ 60 mL/min/1.73 m2, as our patients
were supposed to have the creatinine value \1.5 mg/dL
[28].
Assessment of cardiac autonomic function
Cardiac autonomic function was evaluated by HRV, ob-
tained using time domain method according to previous
recommendations [6, 7]. Electrocardiographic record-
ings—30 min before, during and 30 min after the end of
OGTT—were made by the Holter monitoring system
(CardioNavigator plus, Spacelabs Healthcare, WA, USA)
in supine position. The time domain analysis was ob-
tained by calculating the standard deviation of all nor-
mal-to-normal (SDNN) R–R intervals; the SDNN is
expressed in milliseconds and reflects the parasympa-
thetic drive. The sympathovagal balance was evaluated
by the ratio between low-frequency (LF) components and
high-frequency (HF) components of power spectral
density.
Statistical analysis
Analysis of variance (ANOVA) for clinical and biological
data was performed to test the differences among groups,
and the Bonferroni post hoc test for multiple comparisons
was further performed, as appropriate. Chi-squared test was
utilized for categorical variables. Correlational coefficients
were calculated according to Pearson’s method. Linear
regression analysis was performed to correlate SDNN at
1-h during OGTT with the following covariates: age, BMI,
systolic BP, lipemic parameters, fasting glucose and in-
sulin, 1-h PLPG and insulin, Matsuda index and hs-CRP;
from the analysis, we excluded the e-GFR because there
was no significant difference between groups. After this
analysis, variables reaching statistical significance and
gender, as binary value, were inserted in a stepwise mul-
tivariate linear regression model to determine the inde-
pendent predictors of SDNN. Correlational analysis was
performed for whole study population and according to
different groups of glucose tolerance. Data are reported as
mean ± SD. Differences were assumed to be significant at
P \ 0.05. All comparisons were made using the statistical
package SPSS 16.0 for Windows (SPSS Inc., Chicago, IL,
USA).
Results
Study population
According to OGTT results, study population was divided
into three subgroups: 56 NGT, 20 IGT and 16 with newly
diagnosed type-2 diabetes. The 1-h PLPG cutoff point of
155 mg/dL during OGTT was used to stratify NGT sub-
jects into two groups: 38 patients with 1-h
PLPG \ 155 mg/dL (NGT \ 155) and 18 individuals with
1-h PLPG C 155 mg/dL (NGT C 155).
In Table 1, we reported the demographic, clinical and
biochemical characteristics of the four study groups. There
were no significant differences in gender, age, SBP, DBP,
HDL cholesterol and e-GFR. On the contrary, there were
significant differences for BMI (P = 0.032), fasting glu-
cose and insulin, total (P = 0.006) and LDL cholesterol
(P = 0.005), triglyceride (P = 0.026) and hs-CRP
(P = 0.002). Obviously, during OGTT, in the four groups
of glucose tolerance status, there was a significant
(P \ 0.0001) and progressive increase in glucose and in-
sulin levels associated with a simultaneous significant re-
duction in Matsuda index.
Autonomic function assessment
During OGTT, in patients with type-2 diabetes, SDNN
values progressively decreased through the first hour from
74.3 ± 3.1 to 43.6 ± 12.2 ms (P \ 0.0001) with a slight
but no significant increase during the second hour. Similar
results were observed in IGT subjects, in whom SDNN
decreased from 76.9 ± 17.9 to 54.4 ± 16.7 ms
(P \ 0.0001). Of interest, also in NGT C 155 mg/dL, we
observed a similar trend; in fact, SDNN values decreased
from 70.1 ± 22.4 to 53.8 ± 17.1 ms (P \ 0.0001) during
the first hour, with the total recovery at the end of the
second hour. In NGT \ 155 group, even if we observed a
statistical significance, there were minimal changes in
SDNN values, without any biological and clinical sig-
nificance. In Fig. 1, we graphically reported the SDNN
variations observed during OGTT in the four groups of
glucose tolerance. At the univariate analysis, in the whole
population, we observed a significant relationship between
SDNN at 1-h during OGTT and 1-h PLPG (r = -0.542;
P \ 0.0001), Matsuda index (r = 0.486; P \ 0.0001),
fasting insulin (r = -0.437; P \ 0.0001), fasting glucose
(r = -0.379; P = 0.029), BMI (r = -0.272; P = 0.004),
1-h insulin (r = -0.259; P = 0.006), hs-CRP (r =
-0.198; P = 0.029) and HDL cholesterol (r = -0.174;
P = 0.049).
Successively, in the multivariate analysis, the 1-h PLPG
was retained in the whole population and in NGT C 155
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group as the first significant predictor of SDNN, explaining
the 29.4 and 33.5 % of its variation, respectively. In
NGT C 155 subjects, the hs-CRP was retained as the
second independent predictor explaining another 15.6 % of
SDNN variation (Table 2). Notably, performing the mul-
tivariate analysis with the exclusion of 1-h PLPG as in-
dependent covariate, Matsuda index was retained as the
first predictor of SDNN that explains the 23.6 % of its
variation. These results are not surprising because the in-
sulin secretion follows the glycemic spike, demonstrating
Table 1 Anthropometric and biochemical characteristics of the study population according to glucose tolerance
Variables All NGT \ 155 NGT C 155 IGT Type-2 diabetes P
(N = 92) (N = 38) (N = 18) (N = 20) (N = 16)
Gender (male/female) 36/56 16/22 14/4 9/11 11/5 0.189
Age (years) 54.9 ± 8.6 53.3 ± 8.6 53.5 ± 9.3 57.9 ± 6.5 56.3 ± 9.6 0.195
BMI (Kg/m2) 26.4 ± 3.2 25.7 ± 3.3 26.5 ± 2.4 25.7 ± 3.1 28.4 ± 3.2 0.032
SBP (mmHg) 133.6 ± 9.7 131.5 ± 9.6 135.5 ± 10.2 134.9 ± 7.8 135.0 ± 11.6 0.941
DBP (mmHg) 83.0 ± 8.1 83.5 ± 7.2 82.5 ± 8.7 83.1 ± 7.8 82.1 ± 10.1 0.276
Fasting glucose (mg/dL) 97 ± 13 89 ± 7 100 ± 10 100 ± 10 111 ± 10 \0.0001
1-h glucose (mg/dL) 169.5 ± 56.5 117.6 ± 25.2 182.1 ± 27.1 195.9 ± 28.8 245.4 ± 42.5 \0.0001
2-h glucose (mg/dL) 142.1 ± 53.5 102.8 ± 21.1 118.2 ± 18.3 162.7 ± 15.4 236.5 ± 30.7 \0.0001
Fasting insulin (lU/mL) 9.4 ± 7.0 4.8 ± 1.9 4.9 ± 1.4 15.0 ± 4.4 18.5 ± 7.7 0.0001
1-h insulin (lU/mL) 107.4 ± 50.3 85.6 ± 49.0 114.7 ± 43.0 122.8 ± 52.7 131.8 ± 39.8 0.003
2-h insulin (lU/mL) 125.2 ± 66.9 86.1 ± 52.2 128.1 ± 49.1 146.9 ± 64.7 187.8 ± 60.8 \0.0001
Matsuda index 4.2 ± 2.4 6.3 ± 1.9 4.1 ± 0.9 2.2 ± 0.7 1.5 ± 0.5 \0.0001
Cholesterol (mg/dL) 219.1 ± 22.2 222.4 ± 22.1 204.0 ± 15.7 227.6 ± 23.3 217.6 ± 20.6 0.006
LDL cholesterol (mg/dL) 134 ± 11 135 ± 9 126 ± 12 138 ± 10 136 ± 13 0.005
HDL cholesterol (mg/dL) 48.0 ± 9.2 47.1 ± 9.4 50.2 ± 5.4 47.5 ± 11.7 48.1 ± 9.3 0.713
Triglyceride (mg/dL) 137.0 ± 10.7 137.0 ± 11.1 130.8 ± 10.2 140.0 ± 9.2 140.4 ± 10.0 0.026
hs-CRP (mg/L) 2.6 ± 3.9 2.5 ± 3.0 1.4 ± 1.4 2.2 ± 1.8 4.4 ± 7.4 0.002
e-GFR (mL/min/1.73 m2) 102.1 ± 23.5 102.3 ± 21.5 102.9 ± 33.8 101.8 ± 18.4 101.2 ± 21.8 0.997
Fig. 1 SDNN variations during OGTT in the four groups of glucose
tolerance. In NGT C 155 mg/dL, we observe a progressive reduction
in SDNN values similar to that observed in NGT and type-2 diabetes
patients
Table 2 Multiple linear regression models for SDNN
Partial r2 Total r2 P
All
1-h PLPG 29.4 29.4 \0.0001
NGT C 155
1-h PLPG 33.5 33.5 0.002
hs-CRP 15.6 49.1 0.049
Fig. 2 The figure graphically reports the variations in LF/HF ratio
during OGTT in the four groups. Interestingly, in NGT C 155, we
observe a significant increase at 30 min reaching the value of type-2
diabetes subjects and maintaining the same trend
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that both glucose and insulin increase affect sympathetic
activation.
In Fig. 2, we graphically reported the variations in LF/
HF ratio during OGTT. Basal values and the trend of
sympathovagal balance markedly differ between four
groups. In particular, basal values in IGT and type-2 dia-
betes patients are similar and higher in comparison with
NGT groups. In IGT group, the LF/HF ratio during the
OGTT had a flat trend, while in type-2 diabetes subjects,
we observed a slight increase at 30 min followed by a
plateau until 90 min and a complete recovery at the end of
the test. Clinically relevant, in NGT C 155, we detected a
significant increase at 30 min reaching the type-2 diabetes
subjects’ value and maintaining the same trend observed in
those, with a complete recovery after two hours. In
NGT \ 155 group, the LF/HF showed a slight but no
significant increase during OGTT.
Conclusions
In this study, we demonstrated, for the first time, that a
speedy change in both glucose and insulin levels during
OGTT was able to affect the sympathetic drive and sym-
pathovagal balance in different groups of glucose tolerance
status. Of clinical relevance, both IGT and type-2 diabetes
groups show a sympathetic activity increase, during the
first hour of glucose load, suggesting that also postprandial
glucose and insulin increase could play an important role in
cardiac arrhythmogenesis in patients with different insulin
resistance status. Surprisingly, also NGT C 155 subjects,
during the first 90 min of OGTT, share with type-2 dia-
betes and IGT groups a similar trend for both sympathetic
activation and parasympathetic drive reduction, confirming
that these subjects cannot be considered at low risk, so as
previously demonstrated by us [26]. In fact, we reported
that these subjects have multiple subclinical organ damage,
including cardiac hypertrophy [22] that may be considered
the anatomo-functional substrate over which sympathetic
hyperactivity operates in promoting the appearance of life-
threatening ventricular arrhythmias [29].
Our data, obtained in NGT C 155, demonstrate a
functional change in sympathovagal imbalance that is
likely attributable to differences in plasma glucose or in-
sulin levels during the test since both hyperinsulinemia and
hyperglycemia are sympathoexcitatory. On the other hand,
it cannot be excluded that the sympathovagal modifications
can be due to hyperosmolarity associated with hyper-
glycemia or vasodilation due to hyperinsulinemia and
compensatory increase in sympathetic activity. The pre-
cocity of these functional alterations suggest new clinical
scenarios, especially, with regard to the prognosis and
therapy. Thus, on the basis of these evidences, it might be
possible to confer it a different prognostic significance
because the treatment-related insulin sensitivity improve-
ment could slow the progression of cardiovascular auto-
nomic disorder.
Even if previously published data demonstrated a sig-
nificant relationship between hyperinsulinemia and sym-
pathetic activity increase [30–32], present results,
demonstrating a significant relationship between 1-h PLPG
and SDNN, have a biological plausibility and clinical
relevance. In fact, Hoffman and coworkers reported, in
apparently normal subjects, that acute hyperglycemia
without hyperinsulinemia induces sympathetic neural ac-
tivation, measured by muscle sympathetic nerve activity
[33] as a direct sympathoexcitatory effect of hyper-
glycemia. This suggests that increased sympathetic nervous
system activity and autonomic imbalance may occur also in
subjects with non-symptomatic insulin resistance syndrome
and that also hyperglycemia, per se, is able to promote the
appearance of ventricular arrhythmias with higher risk of
sudden death. Thus, in keeping with this, it is not surprising
that 1-h PLPG was retained as the first independent pre-
dictor of SDNN. On the other hand, it is not possible to
exclude that the SDNN and LH/HF modifications, ob-
served after postload hyperglycemia, are associated with
compensatory hyperinsulinemia, producing a shift in au-
tonomic balance toward increased sympathetic modulation.
The hypothesis that sympathovagal balance is affected by
both glucose and insulin variations is also supported by the
fact that in the multivariate analysis, Matsuda index, re-
flecting the dynamic variations of both glucose and insulin,
was retained as the first predictor of SDNN when we re-
moved 1-h PLPG from the analysis. However, it is relevant
that acute hyperglycemia, directly or by secondary hyper-
insulinemia, by interfering with the sympathovagal bal-
ance, is an important risk factor for the possible occurrence
of life-threatening ventricular arrhythmias, especially in
the postprandial period. In a clinical perspective, this evi-
dence might suggest the importance of carefully monitor-
ing the DAN in order to minimize the arrhythmic risk in
diabetic patients. Finally, the baseline differences between
groups in LF/HF and SDNN consent to hypothesize that the
former is more sensitive to detect subtle baseline differ-
ences than the latter. This difference is probably due to a
different degree of insulin resistance already present at
baseline, as evidenced by the different fasting levels of
both glucose and insulin.
In conclusion, our results confirm that cardiac auto-
nomic imbalance is present in NGT subjects, particularly in
those with 1-h PLPG C 155 mg/dL, similar to that ob-
served in IGT and type-2 diabetes groups. Obviously, this
finding is important for arrhythmic risk stratification.
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Strengths and limitations
The recordings were performed when subjects underwent
an extensive clinic evaluation and they are not necessarily
representative of basal resting conditions. All subjects were
Caucasian, and it is possible that present results may not be
generalizable to other ethnic and racial groups. DAN is a
frequent complication of type-2 diabetes, and the early
subclinical detection of cardiac autonomic dysfunction
may be important for the arrhythmic risk stratification.
Results of this study suggest the clinical utility of sympa-
thovagal balance monitoring in the surveillance of diabetic
patients. Furthermore, prospective studies are needed to
determine whether sympathetic hyperactivity related to
postprandial hyperglycemia contributes to the increased
cardiac mortality.
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